CD4 and neoplasm: Our data demonstrate that the majority of tumor-specific CD4+ T cells differentiated into Th1 cells, consistent with a previous report that the inhibiting of PD-L1 restored CD4+ Th1 cell amplification rapidly, enhancing CD4+ Th1 cytokine production and cytotoxic killing capacity during chronic infection in mice (48).